Dasatinib

Generic Name: Dasatinib

Brand Names: Sprycel

Drug Type: Small Molecule

Chemical Formula: C_₂₂H_₂₆ClN_₇O_₂S

CAS Number: 302962-49-8

Unique Ingredient Identifier: X78UG0A0RN

Background: Dasatinib is an orally available multikinase inhibitor indicated for the treatment of Philadelphia chromosome (Ph)-positive leukemias. Ph is a chromosomal abnormality found in patients with chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL), where the ABL tyrosine kinase and the breakpoint cluster region (BCR) gene transcribe the chimeri...

Indication: Dasatinib is indicated for the treatment of newly diagnosed adults with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase, as well as adults with chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy including imatinib, and adults with Philadelphia chromosome-posi...

Associated Conditions: Accelerated Phase Chronic Myelogenous Leukemia (CML), Acute Lymphoblastic Leukaemias (ALL), Chronic Phase Chronic Myeloid Leukemia, Blast phase Chronic myeloid leukemia

Associated Therapies: -

Clinical Trials

Study of BMS-354825 (Dasatinib) in Patients With Chronic Myeloid Leukemia Who Are Either Resistant or Intolerant to Imatinib

Phase 2

Completed

Conditions: Chronic Myeloid Leukemia
Philadelphia-Positive Myeloid Leukemia

Interventions: Drug: Dasatinib

First Posted Date: 2005-01-13

Last Posted Date: 2012-03-02

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 387

Registration Number: NCT00101660

Locations: 🇬🇧
Local Institution, London, Greater London, United Kingdom
🇨🇭
Local Instituion, Basel, Switzerland

Study of Dasatinib (BMS-354825) in Patients With Accelerated Phase Chronic Myeloid Leukemia

Phase 2

Completed

Conditions: Chronic Myelogenous Leukemia

Interventions: Drug: Dasatinib

First Posted Date: 2005-01-13

Last Posted Date: 2011-04-15

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 197

Registration Number: NCT00101647

Locations: 🇬🇧
Local Institution, London, Greater London, United Kingdom

Dasatinib (BMS-354825) in Subjects With Lymphoid Blast Phase Chronic Myeloid Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

Phase 2

Completed

Conditions: Chronic Myeloid Leukemia
Leukemia, Lymphoblastic, Acute, Philadelphia-positive

Interventions: Drug: Dasatinib

First Posted Date: 2005-01-13

Last Posted Date: 2011-04-14

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 96

Registration Number: NCT00101595

Locations: 🇬🇧
Local Institution, London, Greater London, United Kingdom

Phase I (PH I) Mad Refractory Solid Tumor Study

Phase 1

Completed

Conditions: Neoplasms

Interventions: Drug: Dasatinib

First Posted Date: 2004-12-20

Last Posted Date: 2011-04-19

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 60

Registration Number: NCT00099606

Locations: 🇬🇧
Local Institution, Glasgow, Strathclyde, United Kingdom

Imatinib Mesylate or Dasatinib in Treating Patients With Previously Untreated Chronic Phase Chronic Myelogenous Leukemia

Phase 2

Active, not recruiting

Conditions: Chronic Myeloid Leukemia, BCR-ABL1 Positive

Interventions: Drug: Imatinib Mesylate
Drug: Dasatinib
Other: Laboratory Biomarker Analysis

First Posted Date: 2003-10-07

Last Posted Date: 2024-11-13

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 406

Registration Number: NCT00070499

Locations: 🇺🇸
Valley Radiation Oncology, Peru, Illinois, United States
🇺🇸
Perry Memorial Hospital, Princeton, Illinois, United States
🇺🇸
Swedish American Hospital, Rockford, Illinois, United States

and more 338 locations

BMS-354825 in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Is Resistant to Imatinib Mesylate

Phase 1

Completed

Conditions: Leukemia

First Posted Date: 2003-07-09

Last Posted Date: 2020-08-03

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 42

Registration Number: NCT00064233

Locations: 🇺🇸
Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, California, United States

Fludarabine Phosphate and Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Has Responded to Treatment With Imatinib Mesylate, Dasatinib, or Nilotinib

Phase 2

Completed

Conditions: Recurrent Adult Acute Lymphoblastic Leukemia
Adult Acute Lymphoblastic Leukemia in Remission
Blastic Phase
Childhood Acute Lymphoblastic Leukemia in Remission
Childhood B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Recurrent Childhood Acute Lymphoblastic Leukemia
Recurrent Disease
Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
Chronic Phase of Disease

Interventions: Drug: Cyclosporine
Drug: Dasatinib
Drug: Fludarabine Phosphate
Drug: Imatinib Mesylate
Drug: Mycophenolate Mofetil
Drug: Nilotinib
Procedure: Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation
Procedure: Peripheral Blood Stem Cell Transplantation
Biological: Therapeutic Allogeneic Lymphocytes
Radiation: Total-Body Irradiation

First Posted Date: 2003-01-27

Last Posted Date: 2020-01-29

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 28

Registration Number: NCT00036738

Locations: 🇺🇸
VA Puget Sound Health Care System, Seattle, Washington, United States
🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
🇺🇸
Presbyterian - Saint Lukes Medical Center - Health One, Denver, Colorado, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy